Exscientia (EXAI)
(Delayed Data from NSDQ)
$5.22 USD
+0.11 (2.15%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $5.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EXAI 5.22 +0.11(2.15%)
Will EXAI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EXAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXAI
Amazon (AMZN) Expands AWS Clientele With Exscientia Deal
How Much Upside is Left in Exscientia (EXAI)? Wall Street Analysts Think 61.43%
EXAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect?
Exscientia (EXAI) Upgraded to Buy: Here's What You Should Know
Brian's Big Idea on Healthcare
Other News for EXAI
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
Exscientia Secures Full Rights to Novel Cancer Drug
Exscientia pays GT Apeiron $10M upfont cash+ equity for 'full control' of 617
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD